ArticleFrontiers in oncology2025
Transarterial chemoembolization combined with apatinib in the treatment of advanced hepatocellular carcinoma: a prospective, multi-center, real-world study (Ahend-HAP02).
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To analyze the efficacy and safety of transarterial chemoembolization (TACE) with apatinib (TACE-A) for the treatment of advanced hepatocellular carcinoma (HCC). Methods: Data from advanced HCC patients treated with TACE-A between January 2019 and June 2022 were evaluated. The patients from 8 medical centers were included. The primary endpoints were overall survival (OS) and progression-free survival (PFS). The secondary endpoints were objective response rate (ORR) and adverse events (AEs). Prognostic factors affecting OS were analyzed, and the tumor imaging response at the first follow-up was evaluated to study the survival differences among patients. Results: A total of 389 patients were included, the median PFS was 7.0 months (95% confidence interval [CI]: 6.3-7.7), and the median OS (mOS) was 18.9 months (95% CI: 17.5-20.3). The median time of the first follow-up was 1.2 months, the ORR was 33.7%, and the mOS of the complete response, partial response, stable disease, and progressive disease groups were 30.1, 20.9, 18.5, and 12.9 months, respectively. The difference was statistically significant ( Conclusion: TACE-A significantly improved OS, PFS, and ORR in advanced HCC patients. At the first follow-up patients with a poor tumor response had a poor prognosis. Distant metastasis, maximum tumor diameter, TACE frequency, and AFP levels are important prognostic factors that affect OS in patients. AEs of combination therapy are safe and manageable. Clinical trial number: Chinese Clinical Trials Database (ChiCTR1900024030).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.